CSL 112

Drug Profile

CSL 112

Alternative Names: Apolipoprotein A-I - CSL Behring; CSL-112; CSL112 (reconstituted HDL) - CSL; rHDL - CSL

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CSL
  • Class Antihyperlipidaemics; Cardiovascular therapies; Lipoproteins
  • Mechanism of Action Cholesterol modulators; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atherosclerosis; Myocardial infarction

Most Recent Events

  • 04 Dec 2017 CSL Behring plans the global phase III AEGIS-II trial for Acute coronary syndromes in early 2018
  • 11 Nov 2017 Pharmacokinetics and pharmacodynamics data from the phase IIb AEGIS- I trial in Myocardial infarction presented at the 90th Annual Scientific Sessions of the American Heart Association (AHA-2017)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Atherosclerosis(In volunteers) in Australia (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top